Built to support strategic portfolio growth
.jpg/:/rs=w:1209,h:605,cg:true,m/cr=w:1209,h:605)
Theranoma offers a focused, quality-led path for growth and expansion in any therapeutic area of interest
Our value proposition
Portfolio curation
We help identify products worth evaluating first, based on therapeutic relevance, launch practicality, and commercial logic, taking into account the company long-term strategy.
Flexible manufacturing access
We work with partners that collectively offer:
- Broad OTC, primary care and specialty focus.
- Multiple dosage formats, gums, creams, oral liquids, injectables, tablets, lyophilized products, dry powder injections, liquids, and pre-filled syringe formats.
- Quality pathways ranging from WHO-GMP to EU-GMP, depending on dosage form and site.
Broad network
- Access to global healthcare and pharma players, including Biotech ecosystem
- Close ties with America’s local and regional pharma companies and top distributors
- Connections with top health providers, medical societies and key opinion leaders
.jpg/:/)
Range of services we offer in partnership with Nassa
Theranoma Corp and Nassa partners collaboration to deliver the strongest BD&L avenue for in and out licencing.
Consulting
- Transformative end to end solutions from Business Strategy and Portfolio Management to Patient Support Programs
- Commercial Execution, Digital Marketing, Operational optimization and Human Capital development, including Culture and employee well-being
- Pharmaceutical multi-functional expertise, building impactful solutions where and when you need them
Licensing
- From R&D strategies to market entry, we deliver expert guidance for achieving sustainable growth in a dynamic industry
- We match needs of Multinationals/Originators and local pharma players to maximize the value and life-cycle of every single asset, by defining the ideal deal structure for each case
- Leverage our extensive experience with +50 deals across Latin America and Canada
M&A
- We provide expert support to help to expand your pharmaceutical footprint through acquisitions
- We offer an end-to-end approach: from assets mapping and targeting, moving through due diligence, negotiation, deal closing and monitoring a flawless implementation of the deal
- Our extensive network of stakeholders in the Pharma space will help you speed up and maximize value created through M&A